Exclusive Summary

• • Off-patent and mature: Core patents of Minirin expired; 0.1/0.2 mg tablets are widely genericized in the US/EU, enabling fast distribution entry with clear regulatory paths.
• • Broad patient pools: Covers CDI (rare but lifelong), pediatric primary nocturnal enuresis, and adult nocturia due to nocturnal polyuria, totaling tens of millions of potential users globally.
• • Strong guideline/EML endorsement: Desmopressin is on the WHO EML; major guidelines place it as first-line for CDI and first-line/preferred for enuresis, driving steady, low-substitutability demand.
• • Clear cost edge: Versus originator and ODT/nasal forms, tablets typically deliver 60–90% price cuts, supporting reimbursement, tenders, and hospital switching.
• • Registration- and supply-friendly: With CTD/eCTD, BE, Zone IVb stability, and international GMP, it fits Distribution models to rapidly penetrate emerging markets and fill supply gaps.

Asset Materials

Contact Us for Full Materials